BAY 63–2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile and decreases peripheral vascular resistance in healthy male volunteers

Table 1 Increase in heart rate after oral administration of BAY 63–2521 in solution, compared with placebo.

Dose	Increase in heart rate (beats/minute)	95% confidence interval	P value
0.25 mg	-1.35	(-5.10 to 2.40)	0.4726
0.5 mg	0.44	(-3.45 to 4.32)	0.8218
1.0 mg	4.09*	(1.10 to 7.08)	0.0084
2.5 mg	7.77*	(4.22 to 11.32)	<0.0001
5.0 mg	11.34*	(8.29 to 14.39)	<0.0001